Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J. Clin. 69(1), 7–34 (2019).
  MedlineGoogle Scholar
• 2. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. J. Clin. Oncol. 22(14), 2865–2872 (2004).
  MedlineGoogle Scholar
• 3. Arvold ND, Oh KS, Niemierko A et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res. Treat. 136(1), 153–160 (2012).
  MedlineGoogle Scholar
• 4. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28(20), 3271–3277 (2010).
  MedlineGoogle Scholar
• 5. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12), 2972–2977 (2003).
  MedlineGoogle Scholar
• 6. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer 91(4), 639–643 (2004).
  Medline CASGoogle Scholar
• 7. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15(2), 219–225 (2006).
  Medline CASGoogle Scholar
• 8. Yau T, Swanton C, Chua S et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncolog. 45(2), 196–201 (2006).
  Medline CASGoogle Scholar
• 9. Olson EM, Najita JS, Sohl J et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 22(4), 525–531 (2013).
  MedlineGoogle Scholar
• 10. Pestalozzi BC, Brignoli S. Herceptin(R) (trastuzumab) in cerebrospinal fluid (CSF). Eur. J. Cancer 36(Suppl. 5), S54–S54 (2000).
  MedlineGoogle Scholar
• 11. Stemmler J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Brain metastases in HER2-overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J. Clin. Oncol. 24(18), S64–S64 (2006).
  MedlineGoogle Scholar
• 12. Tsao MN, Rades D, Wirth A et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Practical Radiation Oncol. 2(3), 210–225 (2012).
  MedlineGoogle Scholar
• 13. Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363(9422), 1665–1672 (2004).
  MedlineGoogle Scholar
• 14. Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial. J. Am. Med. Assoc. 295(21), 2483–2491 (2006).
  Medline CASGoogle Scholar
• 15. Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J. Clin. Oncol. 29(2), 134–141 (2011).
  MedlineGoogle Scholar
• 16. Soffietti R, Kocher M, Abacioglu UM et al. A European organisation for research and treatment of cancer Phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J. Clin. Oncol. 31(1), 65–72 (2013). • Clinical trial evaluating the standard of care radiation therapy for brain metastases, expanding on the side effects.
  MedlineGoogle Scholar
• 17. Chang EL, Wefel JS, Hess KR et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10(11), 1037–1044 (2009).
  MedlineGoogle Scholar
• 18. Brown PD, Asher AL, Ballman KV et al. NCCTG N0574 (Alliance): a Phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J. Clin. Oncol. 33(15), (2015). • Clinical trial evaluating the standard of care radiation therapy for brain metastases, expanding on the side effects.
  Google Scholar
• 19. Brown PD, Pugh S, Laack NN et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology 15(10), 1429–1437 (2013).
  Medline CASGoogle Scholar
• 20. Gondi V, Pugh SL, Tome WA et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A Phase II multi-institutional trial. J. Clin. Oncol. 32(34), 3810–U3198 (2014).
  MedlineGoogle Scholar
• 21. Boogerd W, Dalesio O, Bais EM, Vandersande JJ. Response of brain metastases from breast-cancer to systemic chemotherapy. Cancer 69(4), 972–980 (1992).
  Medline CASGoogle Scholar
• 22. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J. Clin. Oncol. 22(17), 3608–3617 (2004).
  MedlineGoogle Scholar
• 23. Peereboom DM. Chemotherapy in brain metastases. Neurosurgery 57(5), 54–65 (2005).
  Google Scholar
• 24. Freilich RJ, Seidman AD, Deangelis LM. Central-nervous-system progression of metastatic breast-cancer in patients treated with paclitaxel. Cancer 76(2), 232–236 (1995).
  Medline CASGoogle Scholar
• 25. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast-carcinoma. Cancer 58(4), 832–839 (1986).
  Medline CASGoogle Scholar
• 26. Walbert T, Gilbert MR. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Internat. J. Clin. Oncol. 14(4), 299–306 (2009).
  Medline CASGoogle Scholar
• 27. Lockman PR, Mittapalli RK, Taskar KS et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clinical Cancer Res. 16(23), 5664–5678 (2010). • Seminal preclinical work demonstrating heterogeneous permeability of systemic therapies in brain metastases.
  Medline CASGoogle Scholar
• 28. Taskar KS, Rudraraju V, Mittapalli RK et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm. Res. 29(3), 770–781 (2012).
  Medline CASGoogle Scholar
• 29. Morikawa A, Peereboom DM, Thorsheim HR et al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-Oncology 17(2), 289–295 (2015). • Seminal translational work demonstrating variability in uptake of systemic therapies in brain metastases.
  Medline CASGoogle Scholar
• 30. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 26(12), 1993–1999 (2008).
  Medline CASGoogle Scholar
• 31. Lin NU, Dieras V, Paul D et al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15(4), 1452–1459 (2009).
  Medline CASGoogle Scholar
• 32. Lin NU, Eierman W, Greil R et al. Randomized Phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J. Neurooncol. 105(3), 613–620 (2011).
  Medline CASGoogle Scholar
• 33. Bachelot T, Romieu G, Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group Phase II study. Lancet Oncol. 14(1), 64–71 (2013).
  Medline CASGoogle Scholar
• 34. Gelmon KA, Boyle FM, Kaufman B et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J. Clin. Oncol. 33(14), 1574 (2015).
  Medline CASGoogle Scholar
• 35. Cameron D, Casey M, Press M et al. A Phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 112(3), 533–543 (2008).
  Medline CASGoogle Scholar
• 36. Swain SM, Kim S-B, Cortes J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 14(6), 461–471 (2013).
  Medline CASGoogle Scholar
• 37. Swain SM, Baselga J, Miles D et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized Phase III study CLEOPATRA. Ann. Oncol. 25(6), 1116–1121 (2014).
  Medline CASGoogle Scholar
• 38. Torres S, Maralani P, Verma S. Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. BMJ Case Reports 2014, bcr2014205680 (2014).
  MedlineGoogle Scholar
• 39. Bartsch R, Berghoff AS, Vogl U et al. Activity of T-DM1 in HER2-positive breast cancer brain metastases. Clin. Experimental Metast. 32(7), 729–737 (2015).
  Medline CASGoogle Scholar
• 40. Krop IE, Kim S-B, Gonzalez-Martin A et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, Phase III trial. Lancet Oncol. 15(7), 689–699 (2014).
  Medline CASGoogle Scholar
• 41. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783–1791 (2012).
  Medline CASGoogle Scholar
• 42. Krop IE, Lin NU, Blackwell K et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann. Oncol. 26(1), 113–119 (2015).
  Medline CASGoogle Scholar
• 43. Freedman RA, Gelman RS, Anders CK et al. TBCRC 022: a Phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J. Clin. Oncol. 37(13), 1081 (2019). •• Clinical trial that leads to the US FDA approval of the first agent for treatment of HER2-positive brain metastases.
  Medline CASGoogle Scholar
• 44. Murthy R, Borges VF, Conlin A et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, Phase Ib study. Lancet Oncol. 19(7), 880–888 (2018).
  Medline CASGoogle Scholar
• 45. Murthy RK, Loi S, Okines A et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N. England J. M. 382(7), 597–609 (2019). •• Phase II clinical trial evaluating tucatinib in treatment of metastatic HER2-positive breast cancer innovative in allowing enrollment of brain metastases patients with potentially promising effects.
  MedlineGoogle Scholar
• 46. Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. Clinical Cancer Res. 19(23), 6404–6418 (2013).
  Medline CASGoogle Scholar
• 47. Canney P, Murray E, Dixon-Hughes J, Lewsley LA, Paul J. A prospective randomised Phase III clinical trial testing the role of prophylactic cranial radiotherapy in patients treated with trastuzumab for metastatic breast cancer - Anglo Celtic VII. Clin. Oncol. 27(8), 460–464 (2015).
  CASGoogle Scholar
• 48. Pivot X, Manikhas A, Zurawski B et al. CEREBEL (EGF111438): a Phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 33(14), 1564 (2015).
  Medline CASGoogle Scholar
• 49. Vern-Gross TZ, Lawrence JA, Case LD et al. Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. J. Neurooncol. 110(3), 381–388 (2012).
  MedlineGoogle Scholar
• 50. Palmieri D, Duchnowska R, Woditschka S et al. Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clinical Cancer Res. 20(10), 2727–2739 (2014). •• Innovative preclinical work that originated the rationale for the proposed secondary prevention of brain metastases clinical trial.
  Medline CASGoogle Scholar
• 51. De Azambuja E, Zardavas D, Lemort M et al. Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Ann. Oncol. doi:mdt359 [pii] 10.1093/annonc/mdt359 (2013).
  Google Scholar
• 52. Neuwelt AJ, Nguyen TM, Fu R et al. Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis. CNS Oncol. 3(4), 267–273 (2014).
  CASGoogle Scholar
• 53. Von Minckwitz G, Huang CS, Mano MS et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380(7), 617–628 (2019).
  Medline CASGoogle Scholar
• 54. Armstrong TS, Gning I, Mendoza TR et al. Clinical utility of the MDASI-BT in patients with brain metastases. J. Pain Symptom Manage. 37(3), 331–340 (2009).
  MedlineGoogle Scholar
• 55. Boire A, Brandsma D, Brastianos PK et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro-Oncology 21(5), 571–583 (2019).
  Medline CASGoogle Scholar
• 56. De Mattos-Arruda L, Mayor R, Ng CKY et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun. 6, (2015). https://doi.org/10.1038/ncomms9839
  MedlineGoogle Scholar
• 57. Brastianos PK, Carter SL, Santagata S et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5(11), 1164–1177 (2015). • Seminal translational work demonstrating genomic evolution of brain metastases which likely impacts therapy responses.
  Medline CASGoogle Scholar
• 58. Karayan-Tapon L, Quillien V, Guilhot J et al. Prognostic value of O-6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J. Neurooncol. 97(3), 311–322 (2010).
  Medline CASGoogle Scholar
• 59. Fitzgerald DP, Palmieri D, Hua E et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin. Experiment. Metast. 25(7), 799–810 (2008).
  MedlineGoogle Scholar
• 60. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nature Reviews Cancer 11(5), 352–363 (2011). •• Interesting discussion of change in paradigm for brain metastases clinical trials.
  Medline CASGoogle Scholar
• 61. Habets EJJ, Dirven L, Wiggenraad RG et al. Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro-Oncology 18(3), 435–444 (2016).
  Medline CASGoogle Scholar
• 62. Caine C, Deshmukh S, Gondi V et al. CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933. J. Neurooncol. 126(2), 327–336 (2016).
  MedlineGoogle Scholar
• 63. Triebel KL, Gerstenecker A, Meneses K et al. Capacity of patients with brain metastases to make treatment decisions. Psychooncology 24(11), 1448–1455 (2015).
  MedlineGoogle Scholar
• 64. Fitzgerald DP, Subramanian P, Deshpande M et al. Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage. Cancer Res. 72(1), 144–153 (2012).
  Medline CASGoogle Scholar
• 65. Alexopoulou AN, Ho-Yen CM, Papalazarou V, Elia G, Jones JL, Hodivala-Dilke K. Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer. BMC Cancer 14, (2014). https://doi.org/10.1186/1471-2407-14-237
  MedlineGoogle Scholar
• 66. Brophy GM, Mondello S, Papa L et al. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J. Neurotrauma 28(6), 861–870 (2011).
  MedlineGoogle Scholar
• 67. Papa L, Silvestri S, Brophy GM et al. GFAP out-performs S100 beta in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions. J. Neurotrauma 31(22), 1815–U1811 (2014).
  MedlineGoogle Scholar
• 68. Zovoilis A, Agbemenyah HY, Agis-Balboa RC et al. microRNA-34c is a novel target to treat dementias. EMBO J. 30(20), 4299–4308 (2011).
  Medline CASGoogle Scholar
• 69. Hoshino A, Costa-Silva B, Shen TL et al. Tumour exosome integrins determine organotropic metastasis. Nature 527(7578), 329 (2015).
  Medline CASGoogle Scholar
• 70. Rodrigues G, Hoshino A, Kenific CM et al. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nature Cell Biol. 21(11), 1403 (2019).
  Medline CASGoogle Scholar